On June 11, Thermo Fisher Scientific fell 3.02% in regular trading, trading at $467.23/share, with turnover of $290 million.
On the news front, Piper Sandler initiated coverage on Thermo Fisher Scientific with a Neutral rating and a $510 price target. This adds to the cautious tone set by HSBC, which previously downgraded the stock from Buy to Hold and slashed its price target from $670 to $540. Multiple institutions now hold a reserved outlook on the stock, creating sustained pressure. The current share price remains well below the analyst consensus target of $602.50.
The broader Life Sciences Tools & Services sector experienced notable weakness, amplifying the downside. Among sector peers, Tempus AI fell 3.44%, Danaher fell 2.82%, IQVIA fell 2.27%, Waters fell 2.09%, and Illumina fell 0.6%, reflecting a significant sector-wide linkage effect.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments